1. Home
  2. EXP vs BLLN Comparison

EXP vs BLLN Comparison

Compare EXP & BLLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Eagle Materials Inc

EXP

Eagle Materials Inc

HOLD

Current Price

$201.25

Market Cap

7.0B

Sector

Industrials

ML Signal

HOLD

Logo BillionToOne Inc.

BLLN

BillionToOne Inc.

HOLD

Current Price

$125.25

Market Cap

6.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EXP
BLLN
Founded
1963
2016
Country
United States
United States
Employees
N/A
713
Industry
Building Materials
Medical Specialities
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.0B
6.0B
IPO Year
1994
N/A

Fundamental Metrics

Financial Performance
Metric
EXP
BLLN
Price
$201.25
$125.25
Analyst Decision
Hold
Buy
Analyst Count
9
7
Target Price
$227.11
$126.71
AVG Volume (30 Days)
407.4K
706.5K
Earning Date
05-19-2026
05-06-2026
Dividend Yield
0.49%
N/A
EPS Growth
N/A
N/A
EPS
13.16
N/A
Revenue
$495,023,000.00
N/A
Revenue This Year
$1.97
$46.29
Revenue Next Year
$1.95
$30.14
P/E Ratio
$15.62
N/A
Revenue Growth
N/A
N/A
52 Week Low
$171.99
$61.96
52 Week High
$245.53
$138.70

Technical Indicators

Market Signals
Indicator
EXP
BLLN
Relative Strength Index (RSI) 40.09 59.90
Support Level $188.79 $79.07
Resistance Level $224.61 $138.70
Average True Range (ATR) 6.82 6.76
MACD -1.70 -0.24
Stochastic Oscillator 4.37 63.99

Price Performance

Historical Comparison
EXP
BLLN

About EXP Eagle Materials Inc

Eagle Materials Inc produces and sells construction products and building materials. Construction products include cement, slag, concrete, and aggregates and building materials include cement and gypsum wallboard, and are sold to the construction and building industries. The firm organizes itself into two sectors: Heavy Materials, which includes the Cement and Concrete and Aggregates segments, and Light Materials, which includes the Gypsum Wallboard and Recycled Paperboard segments.

About BLLN BillionToOne Inc.

BillionToOne Inc is a molecular diagnostics company. It offers a portfolio of ultrasensitive tests covering prenatal genetic testing, cancer therapy selection, and response monitoring, which are based on its Quantitative Counting Templates (QCT) molecular counting platform. The company's product portfolio comprises UNITY, a portfolio of prenatal testing products that can conduct fetal risk analysis without requiring a paternal sample; Northstar Select, a ultrasensitive liquid biopsy test that provides insights into appropriate therapies for stage III or IV cancer patients; and Northstar Response, a tissue-free, pan-cancer, liquid biopsy test that measures several genomic loci uniquely methylated in cancer to provide insight into dynamic changes in therapy response.

Share on Social Networks: